Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-05-31
DOI
10.1038/s41388-018-0288-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Identification of CD112R as a novel checkpoint for human T cells
- (2016) Yuwen Zhu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
- (2016) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Monocyte trafficking across the vessel wall
- (2015) Teresa Gerhardt et al. CARDIOVASCULAR RESEARCH
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
- (2015) Gerhard Zugmaier et al. MOLECULAR IMMUNOLOGY
- Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
- (2015) Tao Dao et al. NATURE BIOTECHNOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Checkpoint blockade in combination with cancer vaccines
- (2015) Michael A. Morse et al. VACCINE
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
- (2014) Man Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
- (2014) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Mechanisms of TIGIT-driven immune suppression in cancer
- (2014) Sema Kurtulus et al. Journal for ImmunoTherapy of Cancer
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
- (2013) Margaret K. Callahan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Vstm3 is a member of the CD28 family and an important modulator of T-cell function
- (2011) Steven D. Levin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Loss of DNAM-1 contributes to CD8+T-cell exhaustion in chronic HIV-1 infection
- (2010) Marina Cella et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
- (2009) M. Carlsten et al. JOURNAL OF IMMUNOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
- (2008) R. G.W. Verhaak et al. HAEMATOLOGICA
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now